Patents Assigned to Nihon Medi-Physics Co., Ltd.
  • Publication number: 20210322582
    Abstract: The present invention provides a radiolabeled compound represented by the following formula (1), which is a radioactive imidazothiadiazole derivative compound having an affinity for CA-IX, or a salt thereof. wherein n is an integer of 1 to 4, and L represents a radionuclide or a mono- to tetravalent group containing a radionuclide.
    Type: Application
    Filed: August 30, 2019
    Publication date: October 21, 2021
    Applicants: Nihon Medi-Physics Co., Ltd., Kyoto University
    Inventors: Masato KIRIU, Norihito NAKATA, Tsutomu ABE, Masahiro ONO
  • Patent number: 11083804
    Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: August 10, 2021
    Assignee: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
  • Publication number: 20210170058
    Abstract: The present invention relates to a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and provides a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.
    Type: Application
    Filed: April 15, 2019
    Publication date: June 10, 2021
    Applicants: NIHON MEDI-PHYSICS CO., LTD., National University Corporation Kagoshima University, National University Corporation Chiba University
    Inventors: Shota KOMOTO, Yu OGAWA, Yoshinari SHOYAMA, Tadashi HATANO, Yuji ITO, Yasushi ARANO, Hiroyuki SUZUKI, Tomoya UEHARA
  • Patent number: 10953112
    Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: March 23, 2021
    Assignee: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
  • Publication number: 20210060186
    Abstract: Provided are a compound represented by the following formula (1): wherein X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represents a radioactive halogen atom, or a salt thereof, and a medicament including the same.
    Type: Application
    Filed: December 20, 2018
    Publication date: March 4, 2021
    Applicants: Nihon Medi-Physics Co., Ltd., National Hospital Organization
    Inventors: Akihiro IZAWA, Yuki OKUMURA, Yurie FUKUI, Hiroaki ICHIKAWA, Yoshifumi MAYA, Miho IKENAGA, Hiroyuki OKUDAIRA, Yoshihiro DOI, Mitsuhide NARUSE
  • Patent number: 10857245
    Abstract: There is provided a diagnostic imaging agent for early bone metastasis from cancer, containing trans-1-amino-[18F]fluorocyclobutanecarboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 8, 2020
    Assignee: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Shuntaro Oka, Masaru Kanagawa, Akiharu Otaka, Masako Teramachi, Satoshi Watanabe, Toshie Nagatomo
  • Patent number: 10703726
    Abstract: A simple method for producing a clinically applicable radiopharmaceutical composition containing 1-(2,2-dihydroxymethyl-3-[18F]fluoropropyl)-2-nitroimidazole ([18F]DiFA) or a salt thereof as an active ingredient, is provided which includes a synthesis step of obtaining a crude product of [18F]DiFA from a labeling precursor compound for [18F]DiFA; and a purification step of purifying the crude product, in which the purification step includes purifying [18F]DiFA using two or more different types of reverse phase solid phase extraction cartridges.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: July 7, 2020
    Assignees: NIHON MEDI-PHYSICS CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Masato Kiriu, Soichi Nakamura, Yuji Kuge, Norifumi Abo
  • Publication number: 20200121811
    Abstract: Provided is a method for producing a radiohalogen-labeled compound, the method comprises: a step in which a radiohalogen-labeling precursor compound (S-L) having a leaving group (L) capable of being nucleophilically substituted by a radioactive halide ion (X?) is subjected to a radiohalogenation reaction to obtain a reaction mixture RM1 which contains the radiohalogen-labeling precursor compound (S-L) and a reaction product (S—X) resulting from the radiohalogenation reaction; a step in which the reaction mixture RM1 is mixed with a polyvalent acid or a salt thereof to obtain a reaction mixture RM2; and a step in which the reaction product (S—X) is purified from the reaction mixture RM2 by a solid phase extraction method.
    Type: Application
    Filed: May 28, 2018
    Publication date: April 23, 2020
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Yuki OKUMURA, Daisaku NAKAMURA, Masato KIRIU, Hiroaki ICHIKAWA, Gota TONOYA, Naomi SUGIMOTO
  • Publication number: 20200009273
    Abstract: There is provided a labeling precursor compound represented by the general formula (2): wherein S represents a substrate, L represents a straight alkyl group having 1 to 6 carbon atoms which may contain an ether group, R1 and R2 each independently represent a straight or branched alkyl group having 1 to 30 carbon atoms, or a substituted or unsubstituted monocyclic or condensed polycyclic aryl group, R3 each independently represent an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms, and p represents an integer of 0 to 4.
    Type: Application
    Filed: March 5, 2018
    Publication date: January 9, 2020
    Applicants: NIHON MEDI-PHYSICS CO., LTD., TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Masato KIRIU, Hiroaki ICHIKAWA, Yuki OKUMURA, Hiroshi TANAKA
  • Patent number: 10472338
    Abstract: Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predetermined general formula; allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18F labeling compound; after the above step, purifying the 18F labeling compound using a reverse phase solid phase extraction cartridge; and removing a protective group to obtain [18F]flutemetamol.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: November 12, 2019
    Assignees: GE HEALTHCARE LIMITED, NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Yuki Okumura, Gota Tonoya, Tomoyuki Matsunami
  • Publication number: 20190276411
    Abstract: A simple method for producing a clinically applicable radiopharmaceutical composition containing 1-(2,2-dihydroxymethyl-3-[18F]fluoropropyl)-2-nitroimidazole ([18F]DiFA) or a salt thereof as an active ingredient, is provided which includes a synthesis step of obtaining a crude product of [18F]DiFA from a labeling precursor compound for [18F]DiFA; and a purification step of purifying the crude product, in which the purification step includes purifying [18F]DiFA using two or more different types of reverse phase solid phase extraction cartridges.
    Type: Application
    Filed: February 28, 2019
    Publication date: September 12, 2019
    Applicants: Nihon Medi-Physics Co., Ltd., National University Corporation Hokkaido University
    Inventors: Masato Kiriu, Soichi Nakamura, Yuji Kuge, Norifumi Abo
  • Patent number: 10395364
    Abstract: One embodiment of the present invention addresses the problem of reducing the influence of physiological accumulation in monitoring nuclear medical image data. To solve this problem, the embodiment includes: extracting a bone area from CT image data having been positioned with nuclear medical image data; in the nuclear medical image data, displaying the data of an area overlapping the bone area extracted above; and, in the nuclear medical image data, not displaying the data of an area not overlapping the bone area extracted above.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: August 27, 2019
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Kazuo Hamada, Hiromitsu Daisaki, Kazumasa Nishida
  • Publication number: 20190255199
    Abstract: The present invention addresses the problem of providing a technique for detecting a lesion of a heart disease in a non-invasive manner. The present invention provides a non-invasive diagnostic imaging agent for a heart disease, which contains a radioactively labeled compound capable of binding to an aldosterone synthase or a salt thereof as an active ingredient.
    Type: Application
    Filed: June 9, 2017
    Publication date: August 22, 2019
    Applicant: Nihon Medi-Physics Co., Ltd.
    Inventor: Yoshifumi MAYA
  • Patent number: 10366479
    Abstract: [Problem to be Solved] To improve stability of automatic normalization of a bone scintigraphy image. [Solution] A preferred embodiment includes: creating a pixel value histogram of image data representing a bone scintigraphy image; setting a plurality of thresholds related to pixel values based on the pixel value histogram; calculating respective average pixel values for the set thresholds; arranging the calculated average pixel values in order from the largest value; and determining a reference value for normalizing the image data based on at least part of a set of the average pixel values arranged in the order. The determining the reference value includes: determining one straight line that approximates a region of small average pixel values out of the set of the average pixel values arranged in the order; and calculating the reference value based on the straight line.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: July 30, 2019
    Assignee: Nihon Medi-Physics Co. Ltd.
    Inventor: Kazuhiro Nishikawa
  • Patent number: 10358434
    Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 23, 2019
    Assignees: NIHON MEDI-PHYSICS CO., LTD., KYOTO UNIVERSITY, NATIONAL HOSPITAL ORGANIZATION
    Inventors: Akihiro Izawa, Kei Akama, Yuki Okumura, Yurie Fukui, Nobuya Kobashi, Tsutomu Abe, Yoshihiro Doi, Miho Ikenaga, Hideo Saji, Hiroyuki Kimura, Mitsuhide Naruse
  • Publication number: 20190169169
    Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 6, 2019
    Applicants: NIHON MEDI-PHYSICS CO., LTD., Kyoto University, National Hospital Organization
    Inventors: Akihiro IZAWA, Kei AKAMA, Yuki OKUMURA, Yurie FUKUI, Nobuya KOBASHI, Tsutomu ABE, Yoshihiro DOI, Miho IKENAGA, Hideo SAJI, Hiroyuki KIMURA, Mitsuhide NARUSE
  • Patent number: 10258247
    Abstract: Provided is a highly reliable technique for the evaluation of ischemic conditions. A preferred embodiment is a nuclear medicine measurement protocol in which the administration of a radiopharmaceutical agent and radiation measurement are performed twice at rest and under stress. In the nuclear medicine measurement protocol, radiation collection is performed without radiopharmaceutical agent administration before the second radiopharmaceutical agent administration, and the result is used to correct the nuclear medicine measurement result after the second radiopharmaceutical agent administration.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: April 16, 2019
    Assignee: Nihon Medi-Physics Co. Ltd.
    Inventors: Kazumasa Nishida, Kazuo Hamada, Kazunori Kobayashi
  • Publication number: 20190055207
    Abstract: Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predetermined general formula; allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18F labeling compound; after the above step, purifying the 18F labeling compound using a reverse phase solid phase extraction cartridge; and removing a protective group to obtain [18F]flutemetamol.
    Type: Application
    Filed: October 17, 2016
    Publication date: February 21, 2019
    Applicants: GE Healthcare Limited, Nihon Medi-Physics Co., Ltd.
    Inventors: Yuki Okumura, Gota Tonoya, Tomoyuki Matsunami
  • Patent number: 10189815
    Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: January 29, 2019
    Assignees: NIHON MEDI-PHYSICS CO., LTD., KYOTO UNIVERSITY, NATIONAL HOSPITAL ORGANIZATION
    Inventors: Akihiro Izawa, Kei Akama, Yuki Okumura, Yurie Fukui, Nobuya Kobashi, Tsutomu Abe, Yoshihiro Doi, Miho Ikenaga, Hideo Saji, Hiroyuki Kimura, Mitsuhide Naruse
  • Patent number: 10080812
    Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: September 25, 2018
    Assignees: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Hideo Saji, Masahiro Ono, Masafumi Ihara, Ikuya Seki